# Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer

> **NCT01693276** · PHASE1,PHASE2 · TERMINATED · sponsor: **Olugbenga Olowokure** · enrollment: 3 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Abraxane
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT01693276
- **Lead sponsor:** Olugbenga Olowokure
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2015-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01693276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01693276, "Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01693276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*